`

Tagged: ADA-SCID

Breakthrough Therapy Designation and Orphan drugs

August 20th, 2020 | ADA-SCID

A Priority Review designation does not alter the scientific/medical standard for approval or the quality of evidence necessary and it does not affect the length of the clinical trial period. Prior to approval, each drug marketed in the United States must go through a detailed FDA review process. FDA drug review time includes two-tiered system […]

Pin It on Pinterest